Clinical Trial Update: Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in HER2-positive gastroesophageal adenocarcinoma; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Stomach
• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Cancer

Drugs mentioned

• FOLFOX
• Trastuzumab (trastuzumab)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Gastric Cancer, Esophageal Cancer | Phase 2 | Status: COMPLETED